Targeted pharma Position digiM’s advanced 3D microstructure analysis as a strategic enabler for pharmaceutical manufacturers aiming to accelerate development timelines and regulatory success, highlighting potential sales to mid-size pharma producers seeking precision QA and faster approvals.

Regulatory uplift Emphasize how predictive insights into product quality and performance can support regulatory submissions, offering a compelling value proposition for quality assurance teams and regulatory affairs departments in pharmaceutical manufacturing.

Digital trust Leverage the broader trend toward digital identity and provenance by aligning digiM’s capabilities with firms pursuing robust product tracing, counterfeit risk mitigation, and auditable data trails within regulated environments.

Growth signals Corporate activity around Digimarc and AI ecosystem integrations signals strong demand for trusted data layers; position digiM as a complementary analytics partner for companies expanding into AI-enabled drug development and automated QA workflows.

Small to mid-market focus With a lean team and modest headcount, target small to midsize pharmaceutical manufacturers that need scalable, high-value analytical capabilities without large-scale enterprise deployments, offering flexible engagement models and rapid ROI.